PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
30.46%
Growth of 30.46% versus flat Drug Manufacturers - Specialty & Generic revenue. Walter Schloss would verify growth quality.
9.53%
Cost growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.40%. Jim Chanos would check for structural cost disadvantages.
41.93%
Growth of 41.93% versus flat Drug Manufacturers - Specialty & Generic gross profit. Walter Schloss would verify quality.
8.79%
Margin change of 8.79% versus flat Drug Manufacturers - Specialty & Generic margins. Walter Schloss would verify quality.
42.65%
R&D change of 42.65% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
17.56%
G&A change of 17.56% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
-7.29%
Marketing expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
173.36%
Other expenses change of 173.36% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify efficiency.
8.78%
Operating expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.61%. Jim Chanos would check for waste.
8.99%
Total costs growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.22%. Jim Chanos would check for waste.
129.01%
Interest expense change of 129.01% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
51.17%
D&A growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.69%. Jim Chanos would check for overinvestment.
147.59%
EBITDA growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.44%. Joel Greenblatt would investigate advantages.
136.32%
Margin change of 136.32% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
82.60%
Operating income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.34%. Joel Greenblatt would investigate advantages.
86.66%
Margin change of 86.66% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
163.77%
Other expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.94%. Jim Chanos would check for issues.
100.85%
Pre-tax income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 10.04%. Joel Greenblatt would investigate advantages.
100.65%
Margin change of 100.65% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
-96.84%
Tax expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
100.85%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 10.67%. Joel Greenblatt would investigate advantages.
100.65%
Margin change of 100.65% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
101.37%
EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 14.00%. Joel Greenblatt would investigate advantages.
100.00%
Diluted EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 14.00%. Joel Greenblatt would investigate advantages.
20.86%
Share count reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.04%. Jim Chanos would check for issues.
61.58%
Diluted share reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.03%. Jim Chanos would check for issues.